Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07121777) titled 'Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Anhui Provincial Hospital
Condition:
Autoimmune Diseases
Intervention:
Drug: Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: August 25, 2025
Target Sample Size: 18
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/...